This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letter to the Editor

Reply to Letter to the Editor “Pharmacologic Properties of Venlafaxine”

Robert L. Findling, Michael A. Schwartz, Daniel J. Flannery, and Michael J. Manos

Published: April 15, 1997

Article Abstract

Letter to the Editor

Sir: We appreciate the interest Dr. Smith has taken in our work which examined venlafaxine in adults with attention- deficit/hyperactivity disorder (ADHD). However, our rationale for initiating a clinical trial with venlafaxine in adults with this syndrome was not simply due to the fact that venlafaxine is an antidepressant. The reason we initiated a trial with venlafaxine was that the effect of venlafaxine on both serotonergic and noradrenergic neural transmission is a pharmacologic profile shared with the tricyclic antidepressants.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 58

Quick Links: